@carculmer, your right, at this point, a generic version of Xarelto is only available in the U.S. in the 2.5 mg dosage, not the 20 mg strength that most people with atrial fibrillation take. Beginning in 2026, Medicare will pay a negotiated “Maximum Fair Price” of $197 for a 30-day supply of Xarelto, but that’s not what patients themselves will pay — individual out-of-pocket costs will depend on each person’s Part D plan copay or coinsurance. For those who aren’t fortunate enough to be on Medicare (or Medicaid), drug companies like Bayer and Johnson & Johnson’s Janssen may try to offset Medicare’s lower negotiated price by charging more to privately insured patients. Hopefully, competitive pressure from insurers, PBMs, and emerging generics — along with public and political scrutiny — will limit how much of that lost revenue they can shift to the commercial market. But history suggests that drug manufacturers will still do everything they can to squeeze every possible penny of profit out of these medications.

@carcu mer
Easy to get from reliable Canadian Soures as Xeralto $175/100 or the generic Revoxoban $ 100./100 pills>
< excuse my rough spelling